Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.64 (market cap $8.54B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Global X NASDAQ 100 Covered Call ETF and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X NASDAQ 100 Covered Call ETF for 51 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| QYLD | SYRE | |
|---|---|---|
Market Cap | $8.54B | $7.52B |
Volume | 2,383,712 | 1,441,031 |
Sector | Income / Options Overlay | Health |
52-Week High | $18.69 | $108.92 |
52-Week Low | $16.70 | $22.18 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF's technical outlook is bullish based on moving averages, but oscillators signal caution with RSI levels above 75 indicating overbought conditions. Recent news highlights its high monthly dividend yield but raises concerns about long-term capital erosion and capped upside due to its covered call strategy, with distributions consistently at $0.18 per share.
The outlook for QYLD is mixed; it offers attractive income with a high yield, appealing for investors seeking monthly cash flow. However, risks include limited growth potential, declining option premiums, and potential tax reclassification of dividends. Analyst sentiment is divided, with some upgrades citing yield attractiveness but others warning of principal erosion over time.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
